Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

Clinical trial NCT05841420 · RECRUITING

Trial details

NCT number: NCT05841420
Sponsor: Morten Ladekarl
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreas Cancer Non-Resectable Pancreas Carcinoma

Start date: 2023-06-12
Primary completion: 2025-06-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.